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Abstract: The catechol isoquinoline derivatives are endogenous compounds present in the mamma-
lian brain and the representative one is referred to as salsolinol. It may be formed from aromatic 
amines leading to neurotoxic N-methyltetrahydroquinolinium ions that may play a role in the etiology 
of Parkinson’s disease (PD). Neuroinflammation and apoptosis is thought to be a major contributor 
to the neuronal degeneration in PD. The alteration of inflammatory cytokines in the brain, cerebral 
spinal fluid and plasma of PD patients supports the existence of functional interconnections between 
the immune and nervous systems. In animal studies, chronic administration of salsolinol induced 
parkinsonian-like symptoms, both peripherally and centrally. However, still little has been known 
about the effects of salsolinol on the pro-inflammatory cytokine production or mast cells activation 
in the gastrointestinal tract. 
Male Wistar rats were subjected to continuous intraperitoneal dosing of salsolinol (200 mg/kg in 
total) with osmotic mini-pumps for two or four weeks and fed with either standard or high fat diet. 
An equivalent group of rats served as the appropriate controls. At the end of the experiment ani-
mals were decapitated and blood samples as well as tissue fragments were collected. Serum samples 
were assayed immunoenzymatically for IL-1β and by liquid chromatography–mass spectrometry for 
histamine. Tissue fragments from gastric antrum, duodenum and proximal colon were formalin fixed, 
paraffin-embedded and stained with either hematoxylin and eosin or toluidine blue.
Once activated, mast cells might secrete a range of neurosensitizing and pro-inflammatory molecules, 
increasing gut-blood and blood-brain barrier permeability. Cytokines mediate the activity of immune 
cells and may affect brain neurochemistry. The results of the present work serve as an additional 
support for the existence of an interrelationship between the nervous and immune system.
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INTRODUCTION
The catechol isoquinoline derivatives are endogenous compounds present in the 
mammalian brain and the representative one is referred to as salsolinol (1-methyl- 
6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline). It may be formed by non-enzymatic 
or enzymatic pathways from aromatic amines leading to neurotoxic N-methyl-
tetrahydroquinolinium ions that may play a role in the etiology of Parkinson’s 
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disease (PD) [1–3]. In animal studies, chronic administration of salsolinol induced 
parkinsonian-like symptoms in the gastrointestinal tract [3–5]. 
So far, neuroinflammation and apoptosis is thought to be a major contributor 
to the neuronal degeneration in the PD. The alteration of inflammatory cytoki-
nes in the brain, cerebral spinal fluid and plasma of PD patients supports the 
existence of functional interconnections between the immune and nervous sys-
tems [6, 7]. The microenvironment of the central and peripheral immune system 
is modified during the pathological process of PD, although it is not clear if these 
changes are secondary to the process of cell degeneration, or if they may play 
an active role in neurodegeneration. Changes in the brain could affect immune 
cells in vivo and these effects could be subsequently transferred to the periphe-
ral immune system. The question of the existence of a systemic inflammation in 
PD, in which cytokines may be possibly involved, might be relevant to the better 
understanding of the pathophysiology of this disease [8].
Cytokines in the gastrointestinal tract are synthesized by activated enterocytes 
and immune cells in the intestinal mucosa as well as by immune and enteric 
glial cells in the muscle layers of the gut. Released cytokines influence the ac-
tivity of many cells, including neurons. Host defense mechanisms involving the 
enteric innervation are not necessarily present under physiological conditions. 
Inflammatory mediators, such as IL-1β and IL-6 enhance gastrointestinal motility 
through direct excitatory actions on a subset of myenteric neurons and through 
the presynaptic inhibition of transmitter release in the enteric nervous system 
(ENS). Once these pro-inflammatory mediators are produced, they can activate 
primary afferent nerves, as well [9]. Recent reports indicate that a pro-inflam-
matory event in the periphery can induce chronic, self-propelling central neuro-
inflammation. The entry of systemic pro-inflammatory factors to the brain may 
result in the activation of microglia to produce more inflammatory factors, which 
may be responsible for neuronal death, suggesting a clinical implication for the 
link between peripheral and central inflammation [8]. 
Information input processed by the enteric nervous system is derived from 
local sensory receptors, the central nervous system and immune cells including 
mast cells. Mast cells (MC) are important effectors of brain-gut axis that translate 
the stress signals into the release of a wide range of neurotransmitters and cyto-
kines, which may profoundly affect the gastrointestinal physiology [10]. Excessive 
activation of mast cells is positively correlated with the severity of allergic and 
inflammatory conditions in the gut. Accumulation of activated or degranulated 
MCs and increased levels of tryptase derived from MCs are found in the intestines 
of patients with inflammatory bowel disease, for example. These results imply that 
activation of mast cells is required for the maintenance of a basal level of mucosal 
homeostasis, but abnormal activation induces intestinal inflammation [11]. What 
is more, nerve-mast cell communication is bi-directional. Antigen-stimulated or 
IgE-activated mast cells act on the ENS. In allergic and inflammatory conditions, 
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a positive feedback loop is established in which mast cells activate nerves that 
further enhance mast cell activity [9].
Immune activation in neurodegenerative diseases is not restricted to brain sites 
and abnormalities in peripheral immune functions in patients with Parkinson’s 
disease have already been reported [8]. Early involvement of the ENS is proposed 
in the pathogenesis of idiopathic Parkinson’s disease, too [12]. Thus the aim of 
this study was primarily, to assess the influence of exogenous salsolinol on the 
serum level of the pro-inflammatory cytokine IL-1β and histamine and secondary, 
to morphologically analyze the gastric and intestinal wall.
MATERIAL AND METHODS
Thirty-two adult male Wistar rats were studied. The animals were housed in 
individual cages. All animals were housed in the same optimal conditions, and 
food and water were provided ad libitum. During experiment, rats were fed with 
either standard diet (2.86 kcal/g, Labofeed, Poland) or with obesity-inducing hi-
gh-fat diet (4.34 kcal/g, Bento Kronen Products, Belgium). The temperature was 
maintained at 23 ± 2oC, and animals were placed on a 12:12 h dark/light cycle. 
The Jagiellonian University Bioethical Committee approved the care and use of 
the animals (ethical approval number — 67/2009).
Rats were either subjected to continuous dosing of salsolinol or served as 
control. Salsolinol (salsolinol hydrochloride, Sigma, USA) in the total dose of 
200 mg/kg was dissolved in 200 μL of 0. 9% solution of salt and delivered by 
ALZET osmotic mini-pumps (Durtec, USA) implanted intraperitoneally. Control 
groups were implanted with ALZET osmotic mini-pumps filled with physiological 
solution of salt (Fig. 1).
Prior to implantation rats were randomly divided into the following groups 
(n = 4 each): (1) rats subjected to continuous dosing of salsolinol for two weeks 
(delivery rate 0.5 μL/h, S1 group) and fed with standard diet throughout the 
entire experimental period; (2) rats subjected to continuous dosing of salsolinol 
for two weeks (delivery rate 0.5 μL/h, SF1 group) and fed with high-fat diet thro-
ughout the entire experimental period; (3) rats subjected to continuous dosing of 
salsolinol for four weeks (delivery rate 0.25 μL/h, S2 group) and fed with standard 
diet throughout the entire experimental period; (4) rats subjected to continuous 
dosing of salsolinol for four weeks (delivery rate 0.25 μL/h, SF2 group) and fed 
with high-fat diet throughout the entire experimental period; (5) a control group 
fed with standard diet for two weeks (C1 group); (6) a control group fed with 
high-fat diet for two weeks (CF1 group); (7) a control group fed with standard 
diet for four weeks (C2 group); (8) a control group fed with high fat-diet for four 
weeks (CF2 group). Rats were starved for 12 hours and operated under general 
anesthesia induced with sodium pentobarbital given intraperitoneally at a dose 
of 0.25 mg/kg (Vetbutal, Biowet, Poland).
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Fig. 1. Implanted osmotic mini-pump in situ (*— mini-pump).
On the last day of the experiment animals were sacrificed and stomachs, small 
and large intestines were removed. All tissue fragments were formalin fixed and 
then paraffin-embedded 5 μm slices were prepared. Specimens were stained with 
either hematoxylin and eosin for the estimation of the severity of inflammation 
or toluidine blue (metachromatic staining) for mast cells analysis [13]. 
During the study, daily food intake and body weight were measured each mor-
ning. For each rat, the amount of daily food intake was determined by weighting 
the amount of food remaining from that given 24 h before. 
The severity of inflammation was examined under optical microscope Axiophot 
(Zeiss, Germany) in each section according to the four criteria, including mucosal 
abrasion, hemorrhage, leukocyte infiltration and edema, adapted from [14]. Mu-
cosal abrasion was defined as erosion of the mucosa. The presence or absence 
of mucosal abrasion per individual field was determined at 100× magnification 
on a scale of 0 — no abrasion and 1 — visible abrasion. The presence or absen-
ce of hemorrhage per individual field was determined at 100× magnification on 
a scale of 0 — no hemorrhage and 1 — visible hemorrhage. Leukocyte infiltrations 
(neutrophils and mononuclear cells) were evaluated in each of the view fields at 
400× magnifications on a scale of 0 — no extravascular leukocytes, 1 — less 
than 20, 2 — 20 to 45 and 3 — greater than 45 leukocytes per high power field. 
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Edema in each view fields was scored at 200 × magnification on a scale of 0 — no 
edema, 1 — mild edema (no alteration in the width of the submucosa), 2 — mo-
derate edema (an increase of less than twice the width of the submucosa) and 
3 — severe edema (an increase of more than twice the width of the submucosa). 
The total score of all view fields was divided by the maximal possible score and 
multiplied by 100, in each category respectively.
The number of mast cells were counted semi-automatically in eight consecutive 
visual fields in five serial slides of stomach (antrum), duodenum and proximal 
colon prepared from every animal, under magnification 125 ×. Images were col-
lected using light microscope Axiophot (Zeiss) equipped with colour camcorder 
ProgRes C12 plus (Jenoptik) and quantified using Multiscan 18.03 Software (CSS, 
Warszawa).
Immediately after decapitation all blood samples were collected and incubated 
for 30 minutes at 4oC for clotting formation. After centrifugation at 1500 g for 
20 min at 4oC (Megafuge 1.0R, Heraeus Instruments), serum samples were col-
lected and frozen at –80oC until further analysis. 
Serum aliquots were prepared from each sample and the level of IL-1β was 
assayed by a quantitative ELISA kit (R&D Systems Europe Ltd) according to the 
manufacturer’s instruction. All measurements were performed in duplicate. 
For histamine assessment, samples of rat sera were purified and concentrated 
using a solid phase extraction (SPE) method for liquid chromatography–mass 
spectrometry (LC/MS). 500 μl of serum was diluted with water to final volume of 
3ml and few portions of formic acid were added to obtain pH = 3. Then samples 
were applied on columns (LiChrolut Merck, C-18, 200 mg, 3 ml). SPE columns 
were washed with 3 ml of 0,1% trifluoroacetic acid (TFA) and were eluted with 
3 ml of 0,1% TFA in 40% acetonitrile. Obtained sample’s eluates were lyophilized 
overnight and dry remainings were reconstituted in 0,1% formic acid for further 
LC/MS analysis. Samples for calibration curve of histamine were prepared in the 
same mode as above.
High-performance liquid chromatography (HPLC) separation was performed on 
a reversed-phase HPLC system (Agillent 1100 series, USA), using a BDS Hypersil 
C18 column (100 mm × 3 mm ID, 3 μm particle size) with a guard column 
(5 mm × 3 mm, 3 μm) (Thermo Scientific, USA). The mobile phase solvents were: 
0,1% formic acid in water (phase A) and 0,1% formic acid in acetonitrile (phase B). 
The HPLC separations were carried out at a flow rate of 300 μl/min with a line-
ar gradient of B in A: from 10% to 95% in 1,5 min, next to 10% in 5 min. In-
jection volume was 25 μl. 
Mass spectrometric detection was performed using an API 2000 triple-quadru-
pole mass spectrometer (Applied Biosystem, USA), with electrospray ionization 
source (temperature 350oC, positive ion mode). For histamine detection multiple 
reaction monitoring (MRM) mode was used with the reaction m/z 113.0–96.0. All 
acquired data were evaluated by Analyst Software (AB Sciex, USA). Concentrations 
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of histamine in rat serum samples were calculated using the standard calibration 
curves, constructed by linear regression analysis plotting of peak area versus 
histamine concentration. The limit of detection of histamine was set at 2 pg/ml.
All data presented are expressed as the mean and standard deviation (SD). 
The results were analyzed using a one-way analysis of variance (ANOVA) followed 
by post hoc tests. All statistical tests were performed using STATISTICA software 
package (StatSoft, Tulsa, USA). Statistical significance was set at p <0.05.
RESULTS
1. BODY WEIGHT AND FOOD INTAKE
Chronic intraperitoneal treatment with salsolinol significantly diminished the 
mean weight gain and the mean food consumption in rats fed with both stan-
dard and high fat diet, in comparison with relevant control group of animals 
(p <0.05) (Table 1).
T a b l e  1
Total food intake and body mass gain in animals fed with standard and high-fat diet  
after intraperitoneal salsolinol administration.
Groups
S1 C1 SF1 CF1
Body mass gain (%)
over initial body weight 23.3 * 32.4 29.1 * 44.5
Total food intake (g) 340.4 ± 15.2 360.2 ± 24.6 238.7 ± 26.6 253.5 ± 36.3
S2 C2 SF2 CF2
Body mass gain (%)
over initial body weight 42.2 * 51.8 41.7 * 71.7
Total food intake (g) 644.3 ± 55.1 696.9 ± 39.1 429.3 ± 36.3 509.3 ± 24.1
Two weeks of salsolinol exposure: S1 — standard diet, SF1 — high fat diet, together with control groups; C1 — 
standard diet, CF1 — high fat diet; four weeks of salsolinol exposure: S2 — standard diet, SF2 — high fat diet, 
together with control groups; C2 — standard diet, CF2 — high fat diet; * p <0.05.
2. HISTOLOGICAL ANALYSIS
Neither chronic intraperitoneal treatment with salsolinol nor the high fat diet led 
to formation of inflammatory lesions along the gastrointestinal tract of rats. There 
were no signs of pathological patterns, such as mucosal abrasion and edema, 
hemorrhage or leukocyte infiltration in the routine biopsies from gastric antrum, 
duodenum or proximal colon stained with hematoxylin and eosin. There were no 
visible changes between all the experimental groups (Table 2, Fig. 1). 
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T a b l e  2
Inflammatory index score after intraperipheral chronic salsolinol administration.
Groups Mean (%) ± SD Groups Mean (%) ± SD
S1 21.01 ± 10.61 S2 23.44 ± 13.78
C1 25.52 ± 11.95 C2 22.40 ± 14.34
SF1        27.78 ± 9.26 SF2 19.62 ± 11.72
CF1 25.35 ± 12.72 CF2 24.48 ± 22.63
Two weeks of salsolinol exposure: S1 — standard diet, SF1 — high fat diet, together with control groups; C1 — 
standard diet, CF1 — high fat diet; four weeks of salsolinol exposure: S2 — standard diet, SF2 — high fat diet, 
together with control groups; C2 — standard diet, CF2 — high fat diet.
3. HISTOLOGICAL ANALYSIS OF MAST CELLS
The total number of metachromatic cells (mast cells) was evaluated in every 
histological sample from gastric antrum, duodenum and proximal colon (Table 3).
T a b l e  3
Mast cells count in the stomach, duodenum and proximal colon in animals fed with standard and 
high-fat diet after intraperitoneal salsolinol administration.
Groups
Stomach Duodenum Proximal colon
Mean ± SD Mean ± SD Mean ± SD
S1  169.0 ± 100.8 14.0 ± 9.1 18.7 ± 13.4
C1 115.4 ± 62.2  5.2 ± 2.1 12.8 ± 14.0
SF1  192.3 ± 103.7  16.0 ± 10.5 17.3 ± 11.6
CF1 110.9 ± 78.2  7.8 ± 7.8 16.7 ± 11.2
S2 212.6 ± 84.3 18.4 ± 8.6 22.3 ± 22.1
C2 133.9 ± 73.3 11.7 ± 8.9         16.4 ± 8.6
SF2  188.6 ± 107.2  23.7 ± 22.8 23.7 ± 22.8
CF2  145.7 ± 122.6  16.3 ± 11.5 19.4 ± 15.4
Two weeks of salsolinol exposure: S1 — standard diet, SF1 — high fat diet, together with control groups; C1 — 
standard diet, CF1 — high fat diet, four weeks of salsolinol exposure: S2 — standard diet, SF2 — high fat diet, 
together with control groups; C2 — standard diet, CF2 — high fat diet.
The total number of MC in the gastrointestinal wall was increased significantly 
in all salsolinol-treated rats, especially in the gastric antral region (Fig. 2). We 
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assumed that high fat diet was responsible for the increase in the number of 
mast cells within the gastrointestinal wall, however not statistically significant.
4. SERUM LEVEL OF HISTAMINE
The serum levels of histamine were elevated in both groups of salsolinol-treated 
rats (S1 and S2) in comparison with the appropriate control groups (Table 4).
T a b l e  4
The serum level of histamine (ng/ml) in animals fed with standard diet after intraperitoneal  
salsolinol administration.
Groups Mean (%) ± SD Groups Mean (%) ± SD
S1  591.837 ± 488.414 S2 405.376 ± 222.508
C1 121.473 ± 79.428 C2 313.156 ± 184.936
Two weeks of salsolinol exposure: S1 — standard diet together with control group C1 — standard diet; four weeks 
of salsolinol exposure: S2 — standard diet together with control group C2 — standard diet.
Fig. 2. Mast cells in the rat stomach wall (cross-section) after toluidine blue staining. Mast cells 
red-purple (metachromatic staining) and the background blue (orthochromatic staining).  
Magnification 400×.
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5. SERUM LEVEL OF INTERLEUKIN-1b
Chronic intraperitoneal salsolinol administration increased pro-inflammatory 
IL-1β levels in all experimental groups compared to relevant controls (Fig. 3). The 
highest values were present in animals given salsolinol for four weeks (S2 group). 
The high-fat diet did not influence the IL-1β levels in rats. 
Fig. 3. The serum level of interleukin-1β (pg/ml); two weeks of salsolinol exposure: S1 — standard 
diet, SF1 — high fat diet, together with control groups; C1 — standard diet, CF1 — high fat diet; 
four weeks of salsolinol exposure: S2 — standard diet, SF2 — high fat diet, together with control 
groups; C2 — standard diet, CF2 — high fat diet; *p <0.05.
DISCUSSION
The course of PD progression is hugely debated, although one leading hypothesis 
postulates that PD pathology begins in the enteric plexus or olfactory bulb and 
works its way into the central nervous system in appropriate stages. Neuroactive 
substances are usually taken up at synapses, where they are controlled by re-
ceptor-mediated endocytosis and transported to the cell body via the axon. The 
absence of a myelin sheath around axons of the first neuron in the potential chain 
of vulnerable projections may facilitate entrance and damage by unknown toxins 
or pathogens. Most of the neurons located within the gastrointestinal wall, in-
trinsic enteric neurons, extrinsic preganglionic parasympathetic and sympathetic 
fibres, lack such a shielding barrier [12]. Salsolinol and its active metabolites may 
as well, for example, participate in the equilibrium of information transmission 
at synapses [3]. 
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Jang et al. have recently supported the Braak-like progression of pathology. 
They demonstrated that a pathogenic virus was sufficient to induce toxicity in 
nigral DA neurons. The study also implicated inflammation as a significant factor 
in extra-nigral and Lewy body histopathology. Data such as these indicate the 
potential of inflammation to contribute to non-motor symptoms in PD [15]. Inflam-
mation is a vital cellular response, however, when prolonged, it overrides the bo-
unds of physiological control, eventually becomes destructive and may permeate 
all levels of dysfunction associated with PD, including non-motor symptoms [16].
Recognition that an extensive communication exists between the immune 
system and the nervous system is one of the most fundamental advances in 
the recent neuroscience. In fact, mast cells may represent such an undervalu-
ed peripheral link to the nervous tissue in an inflammatory setting. Mast cells 
participate in innate host defense reactions, are capable of phagocytosis and 
antigen presentation and can modulate the adaptive immune response [17]. In 
our experiment, neither chronic intraperitoneal treatment with salsolinol (total 
dose of 50 mg of racemic salsolinol hydrochloride) nor the high fat diet led to 
formation of inflammatory lesions along the gastrointestinal tract of rats. However, 
the total number of MC in the gastrointestinal wall was significantly increased 
in all salsolinol-treated rats, especially in the gastric antral region. We assumed 
that high fat diet was responsible for the increase in the number of mast cells 
within the gastrointestinal wall. Our previous results showed mucosal mast cells 
depletion and increase in the degranulated cells, which we suggest should be 
due to excessive mast cells degranulation caused by acute salsolinol treatment 
(50 mg of salsolinol hydrochloride daily) [18]. Mast cells, once activated may se-
crete a range of neurosensitizing compounds [10]. In our experiment, the serum 
levels of histamine were significantly elevated in all salsolinol-treated rats in com-
parison with the control groups. However, histamine is not the only MC-derived 
mediator taking part in the interaction between MCs and ENS. A whole array of 
cytokines plays a central role in this interaction, but such data are only beginning 
to accumulate. The mast cells-enteric nerves interaction is not a one-sided rela-
tionship [19]. Indeed, the consequences of vagus nerve stimulation, for example, 
and mediator release on intestinal mast cells function have caught researchers’ 
interest in recent years [13, 20]. 
Morphological and functional studies have provided evidence that apart 
from the interaction between the enteric nervous system and mast cells there is 
also a functional communication between the central nervous system and mast 
cells [10]. Communication between the central nervous system and mast cells in 
the gut mucosa may occur through various pathways, of which the most impor-
tant occurs to be through intrinsic reflexes. Both mast cells and sensory neurons 
code information by releasing chemical message that is decoded by numerous 
processing circuits in the nervous system [21]. Reports of Pavlovian conditioning 
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of enteric mast cell degranulation give direct evidence for a brain-mast cell con-
nection [22].
Chen et al. reported that men with elevated plasma levels of interleukin-6 have 
an increased risk of developing PD. IL-6 has both pro-inflammatory and anti-in-
flammatory activities [23]. IL-1β is a potent pro-inflammatory cytokine that acts 
through IL-1 receptors found on numerous cell types including neurons and 
microglia. IL-1 signaling leads to NF-κB mediated expression of pro-inflamma-
tory cytokines. In PD patients, IL-1β is elevated in cerebrospinal fluid, striatum 
and substantia nigria. Over-expression of IL-1β in these patients may lead to an 
increased neuron’s, probably especially dopaminergic, vulnerability to exogenous 
toxins and an increased risk for PD onset [24]. What is more, blood brain bar-
rier disruption has already been demonstrated in different systemic infections as 
a result of the activation of various mediators that cause multiple organ failure 
including the brain. Microglia of the blood origin may also activate the immune 
system and lead to central damage [25]. For example, it has been reported that 
bone marrow-derived microglial cells add to the neuroinflammatory response and 
express iNOS in the MPTP mouse model of PD [26]. These findings indicate that 
systemic infection may be a significant risk factor in the genesis of Parkinson’s 
disease. Neurons have been shown to be particularly susceptible to IL-1β-media-
ted toxicity [27]. In our experiment, intraperitoneal salsolinol treatment increased 
peripheral IL-1β production. However, the relevance of these findings to PD pa-
thogenesis should be further evaluated in every detail. 
Significant evidence linking systemic inflammation with neurodegeneration 
comes mainly from epidemiological studies. Changes in peripheral immune fac-
tors can undoubtedly influence neurodegenerative processes [27]. What is more, 
neuroinflammation may also raise the brain’s sensitivity to stress [17]. The role 
of inflammation in PD has been suggested over the last 20 years by a number of 
studies, showing microglia activation, cytokine production and oxidative damage 
in vivo and post-mortem, although the precise role of inflammation in the path-
ogenesis of PD remains unclear [28]. The results of the present work serve as an 
additional support for the existence of an interrelationship between the nervous 
and immune system. We are convinced that the emerging information on the 
brain and systemic immune as well as nervous system communication, especially 
early in the disease progression, will provide us with a window of opportunity to 
target early symptoms of Parkinson’s disease.
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